MPG.eBooks - Description: CDEC final recommendation: Dolutegravir (Tivicay -- ViiV Healthcare ULC)

Cover Image

Read Now

CDEC final recommendation: Dolutegravir (Tivicay -- ViiV Healthcare ULC) indication : HIV infection

The Canadian Drug Expert Committee (CDEC) recommends that dolutegravir be listed for the treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older weighing at least 40 kg

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health August 18, 2014, 2014
Series:	Common drug review
Subjects:	Canada Hiv Integrase Inhibitors / Therapeutic Use Cost-benefit Analysis Heterocyclic Compounds, 3-ring / Therapeutic Use Hiv Infections / Drug Therapy Treatment Outcome
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK534069
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The Canadian Drug Expert Committee (CDEC) recommends that dolutegravir be listed for the treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older weighing at least 40 kg
Physical Description:	1 PDF file (7 pages)